Each 30 g of spray also contains benzyl alcohol 0.5 g, sodium edetate 0.0025 g, methylparaben 0.025 g, anise oil 0.03 g, ammonium glycyrrhizinate 0.02 g, sodium saccharin 0.05 g, microcrystalline cellulose and carboxymethylcellulose 0.3 g, soybean lecithin 0.9 g, glycerol 1 g, 95% alcohol 1.06 g, purified water and nitrogen as excipients.
Microbiology: Biclotymol has bacteriostatic and bactericidal properties particularly against gram-positive bacteria. It was found to have fungistatic activity (dermatophyte fungi, blastomyces, histoplasma, paracoccidioides) and anti-inflammatory and analgesic effects.
Pharmacokinetics: Absorption through buccal and oropharyngeal mucosa is very slow.
Toxicology: Preclinical Safety Data: Biclotymol LD50 following oral administration in the rat was found to be 11 g/kg and >10 g/kg in the mouse. No abnormal behaviour and no mortality were noticed in the rat with administrations of Hexaspray via the digestive tract using an oesophageal tube during 45 days and in the beagle dog by spraying on the pharyngeal mucosa the equivalent of 4-20 therapeutic doses.
Local symptomatic treatment of acute oropharyngeal disorders.
In case of systemic manifestations of bacterial infection, antibiotherapy must be considered.
Adults and Children: 2 nebulizations 3 times/day. Shake the bottle before each use. Handle vertically while spraying.
As a rule, throat sprays are contraindicated in children and infants <30 months (risk of laryngospasm).
Treatment should not exceed 5 days. Beyond that period, patient management should be considered.
Keep away from heat.
Shelf-Life: 5 years.
R02AA - Antiseptics ; Used in throat preparations.
Hexaspray throat spray 0.75 g/30 g
30 g x 1's
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
